1SB-LSD

1SB-LSD
Clinical data
Other names1BS-LSD; 1-(4-(Trimethylsilyl)benzoyl)-LSD
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Chemical and physical data
FormulaC30H36N3O2Si
Molar mass498.722 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C]1CN(C)[C@@H]2Cc3cn(C(=O)c4ccc(cc4)[Si](C)(C)C)c5cccc(C2=C1)c35
  • InChI=1S/C30H36N3O2Si/c1-7-32(8-2)29(34)22-16-25-24-10-9-11-26-28(24)21(17-27(25)31(3)18-22)19-33(26)30(35)20-12-14-23(15-13-20)36(4,5)6/h9-16,19,27H,7-8,17-18H2,1-6H3/t27-/m1/s1
  • Key:SLFZGAWRMZEIEW-HHHXNRCGSA-N

1SB-LSD, or 1BS-LSD, also known as 1-(4-(trimethylsilyl)benzoyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is thought to be a prodrug of LSD.[1] The drug was encountered online as a novel designer drug in September 2025.[1] 1SB-LSD has been sold in the form of blotter containing 165 μg per tab.[1] It is the derivative of 1Bz-LSD (SYN-L-018) in which there is a 4-trimethylsilyl group on the benzyl ring.[1][2] 1SB-LSD is not an explicitly controlled substance in the United States[3] or in Canada.[4]

See also

References

  1. ^ a b c d e f "1BS-LSD". AIPSIN (in Russian). Retrieved 1 January 2026.
  2. ^ WO 2024/028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV 
  3. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  4. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.